Information in relation to COVID-19
GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the outbreak and spread of COVID-19 followed the development and effects closely. The company has taken proactive measures to ensure continuity of the global Phase 3 AGENT study, which will continue to enrol patients in line with regulatory guidelines and site capabilities.The spread of the COVID-19 pandemic is effecting societies and companies all over the world and will have a significant impact on the global healthcare system. Many hospitals, regions and countries